Pelthos Therapeutics Inc. Common Stock (PTHS)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Pelthos traded at $20.29, giving a $77.7M market cap. FairStock's calculations show a P/B of 2.56 and a negative P/E of -0.71; neither is comforting for a company with no profits. More important, the business is not generating cash: trailing free cash flow was -$50.5M, a -65.0% FCF yield. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $15.6M and net income was -$23.4M, or diluted EPS -$6.62. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $10.9M and net income was -$25.1M, or diluted EPS -$3.09. Full-year fiscal 2025 revenue was $16.8M with net income -$43.3M and diluted EPS -$23.04. Fiscal 2024 and 2023 had no revenue reported and net losses of -$8.0M and -$7.4M. So while sales are appearing, losses are widening, and the latest quarter's net margin was -150.08%. The company has marketed products—ZELSUVMI, XEPI, XEGLYZE—but from the figures I cannot see a durable competitive moat. Financial health is poor: D/E 1.51, Altman Z -0.85, Piotroski 3/9, FairStock score 30/100. Lynch category is none because it lost money each of last four years. Beta 3.05 adds volatility. At 2.56 times book and a large cash burn, the price does not offer a margin of safety by Graham's arithmetic. Growth in revenue is promising, but profitability and cash generation are not yet in evidence.

In plain English: Pelthos Therapeutics makes medicines for skin and infection conditions. The business looks weak: it has lost money for years, uses a lot of cash, and has no profits. At $20.29 on 2026-10-13, the price does not look cheap compared with those results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer